Fiche publication
Date publication
janvier 2025
Journal
Theranostics
Auteurs
Membres identifiés du Cancéropôle Est :
Dr GARRIDO Carmen
,
Dr GONCALVES Victor
,
Dr COLLIN Bertrand
,
Dr BELLAYE Pierre-Simon
,
Pr BONNIAUD Philippe
,
Dr DIAS Alexandre
Tous les auteurs :
Dias AMM, Burgy O, Moreau M, Goncalves V, Pommerolle L, Douhard R, Courteau A, Helbling A, Guillemin M, Simonet J, Oudot A, Garrido C, Bonniaud P, Goirand F, Collin B, Bellaye PS
Lien Pubmed
Résumé
Idiopathic pulmonary fibrosis (IPF) is a progressive disease characterized by an excessive collagen deposition ultimately leading to tissue stiffening and functional decline. Beyond IPF, other progressive pulmonary fibrosis are often associated with connective tissue diseases and may develop in ∼18-32% of patients. Therapeutic options are limited to nintedanib and pirfenidone which are only able to reduce fibrosis progression without curing it. The current lack of biomarker to accurately assess and predict disease progression and therapy efficacy for IPF remains a major clinical concern. In our study, collagen deposition was monitored in bleomycin-induced lung fibrosis in mice by molecular imaging using a collagen-targeted radiopharmaceutical, [Ga]Ga-NODAGA-collagelin. Fibrosis progression was also monitored using computed tomography, the gold standard technique to detect lung fibrosis in patients. We demonstrated that the bleomycin-induced increase in collagen lung content can be accurately quantified by [Ga]Ga-NODAGA-collagelin PET imaging in correlation with disease stage and severity. The lung uptake of [Ga]Ga-NODAGA-collagelin was mainly found in fibrotic areas of lungs in bleomycin-receiving mice. Most interestingly, [Ga]Ga-NODAGA-collagelin PET imaging allowed the non-invasive monitoring of nintedanib efficacy as well as the anti-fibrotic effect of the JAK inhibitor, tofacitinib. Thus, collagen-targeted PET imaging appears as a promising non-invasive tool for staging, monitoring and prediction of disease progression and therapy efficacy towards personalized medicine in IPF.
Mots clés
Animals, Bleomycin, Mice, Collagen, metabolism, Positron-Emission Tomography, methods, Gallium Radioisotopes, Lung, diagnostic imaging, Radiopharmaceuticals, Disease Models, Animal, Disease Progression, Idiopathic Pulmonary Fibrosis, diagnostic imaging, Mice, Inbred C57BL, Heterocyclic Compounds, 1-Ring, Pulmonary Fibrosis, diagnostic imaging, Antifibrotic Agents, pharmacology, Tomography, X-Ray Computed, methods, Indoles, pharmacology, Acetates
Référence
Theranostics. 2025 01 13;15(6):2092-2103
